Compass Pathways' Psilocybin Therapy Shows Sustained Efficacy in Year-Long TRD Trial — Compass Pathfinder Limited

Event summary

Compass Pathways' Phase 3 COMP005 trial shows 13-point MADRS score reduction at 52 weeks with additional COMP360 psilocybin dosing.
Open-label Part C data demonstrates 40-45% response rates and ~30% remission rates post-treatment.
FDA rolling NDA submission for COMP360 expected in Q4 2026 with potential 2027 launch.
Trial involved 258 participants with treatment-resistant depression across the U.S.

The big picture

Compass Pathways' positive Phase 3 results position COMP360 as a potential game-changer in treatment-resistant depression, offering rapid onset and sustained efficacy with infrequent dosing. The data supports a differentiated profile compared to existing antidepressants, which typically require daily administration. The company's progress comes as mental health disorders continue to rise globally, with the WHO projecting depression as the leading cause of disease burden by 2030.

What we're watching

Regulatory Approval: Whether the FDA will grant accelerated approval for COMP360 based on the Phase 3 data.
Market Positioning: How Compass Pathways will differentiate COMP360 in the emerging psychedelic therapeutics market.
Commercialization Strategy: The pace at which Compass can establish reimbursement pathways for COMP360 post-approval.